When orphan drugs are still at the early stages of development,the latest and most accurate information is required for the drug to advance efficiently. Fleming Europe organizes the 2nd Annual Orphan Drug Congress 2012,where worldwide pharmaceutical experts will share their experiences and insight.
KEY TOPICS
Successful development plan for Orphan Drug Regulatory challenges surrounding Orphan drug development Developing patient registries Commercial aspects of orphan drug development Patient perspective
+ PLUS
Ms Sharon Terry (President and CEO of Genetic Alliance) will open the first day of the conference with keynote presentation “A team of teams: Orphan drug development” President of OrphaNet Ms Segolene Ayme will present International Rare Disease Research Initiative
Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging dueto its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
